Loading…

The Clinical Significance of O 6 -Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis

Promoter status of O -methylguanine-DNA methyltransferase ( ) has been widely established as a clinically relevant factor in glioblastoma (GBM) patients. However, in addition to varied therapy schedule, the prognosis of GBM patients is also affected by variations of age, race, primary or recurrent t...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in neurology 2018-03, Vol.9, p.127
Main Authors: Zhao, Yu-Hang, Wang, Ze-Fen, Cao, Chang-Jun, Weng, Hong, Xu, Cheng-Shi, Li, Kai, Li, Jie-Li, Lan, Jing, Zeng, Xian-Tao, Li, Zhi-Qiang
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page 127
container_title Frontiers in neurology
container_volume 9
creator Zhao, Yu-Hang
Wang, Ze-Fen
Cao, Chang-Jun
Weng, Hong
Xu, Cheng-Shi
Li, Kai
Li, Jie-Li
Lan, Jing
Zeng, Xian-Tao
Li, Zhi-Qiang
description Promoter status of O -methylguanine-DNA methyltransferase ( ) has been widely established as a clinically relevant factor in glioblastoma (GBM) patients. However, in addition to varied therapy schedule, the prognosis of GBM patients is also affected by variations of age, race, primary or recurrent tumor. This study comprehensively investigated the association between promoter status and prognosis in overall GBM patients and in different GBM subtype including new diagnosed patients, recurrent patients and elderly patients. A comprehensive search was performed using PubMed, EMBASE, Cochrane databases to identify literatures (published from January 1, 2005 to April 1, 2017) that evaluated the associations between promoter methylation and prognosis of GBM patients. Totally, 66 studies including 7,886 patients met the inclusion criteria. Overall GBM patients with a methylated status of receiving temozolomide (TMZ)-containing treatment had better overall survival (OS) and progression-free survival (PFS) [OS: hazard ratio (HR) = 0.46, 95% confidence interval (CI): 0.41-0.52,  
doi_str_mv 10.3389/fneur.2018.00127
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_29619003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>29619003</sourcerecordid><originalsourceid>FETCH-LOGICAL-p108t-c58c6eebee42f757d775f5e8d7e9ad6a5c87e5d1b9285d4ce6d5acab574e9813</originalsourceid><addsrcrecordid>eNpNUMtOwkAUnRiNEGTvyswPFDst83JHUNEEhQQSl-S2cwtjplPSmS74Eb_XRjTxbM4rOYtDyC1LJ3mu9H3lsWsnWcrUJE1ZJi_IkAkxTbJM88t_ekDGIXymPXKtc5Ffk0GmBdO9H5Kv7QHp3FlvS3B0Y_feVr30JdKmoisqaPKG8XBy-w689Zg8vs_oOYkt-FBhCwHpum3qJmL7W0G0jaebCLEL1Ho6M52LdN3H6GOgHzYe6MLZpnAQYlPDA_0ZhQQ8uFOw4YZcVeACjn95RLbPT9v5S7JcLV7ns2VyZKmKSclVKRALxGlWSS6NlLziqIxEDUYAL5VEblihM8XNtERhOJRQcDlFrVg-Infn2WNX1Gh2x9bW0J52f__k36RTbHE</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Clinical Significance of O 6 -Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis</title><source>PubMed Central</source><creator>Zhao, Yu-Hang ; Wang, Ze-Fen ; Cao, Chang-Jun ; Weng, Hong ; Xu, Cheng-Shi ; Li, Kai ; Li, Jie-Li ; Lan, Jing ; Zeng, Xian-Tao ; Li, Zhi-Qiang</creator><creatorcontrib>Zhao, Yu-Hang ; Wang, Ze-Fen ; Cao, Chang-Jun ; Weng, Hong ; Xu, Cheng-Shi ; Li, Kai ; Li, Jie-Li ; Lan, Jing ; Zeng, Xian-Tao ; Li, Zhi-Qiang</creatorcontrib><description>Promoter status of O -methylguanine-DNA methyltransferase ( ) has been widely established as a clinically relevant factor in glioblastoma (GBM) patients. However, in addition to varied therapy schedule, the prognosis of GBM patients is also affected by variations of age, race, primary or recurrent tumor. This study comprehensively investigated the association between promoter status and prognosis in overall GBM patients and in different GBM subtype including new diagnosed patients, recurrent patients and elderly patients. A comprehensive search was performed using PubMed, EMBASE, Cochrane databases to identify literatures (published from January 1, 2005 to April 1, 2017) that evaluated the associations between promoter methylation and prognosis of GBM patients. Totally, 66 studies including 7,886 patients met the inclusion criteria. Overall GBM patients with a methylated status of receiving temozolomide (TMZ)-containing treatment had better overall survival (OS) and progression-free survival (PFS) [OS: hazard ratio (HR) = 0.46, 95% confidence interval (CI): 0.41-0.52,  &lt; 0.001, Bon = 0.017; PFS: HR = 0.48, 95% CI 0.40-0.57,  &lt; 0.001, Bon = 0.014], but no significant advantage on OS or PFS in GBM patients with TMZ-free treatment was observed (OS: HR = 0.97, 95% CI 0.91-1.03,  = 0.08, Bon = 1; PFS: HR = 0.76, 95% CI 0.57-1.02,  = 0.068, Bon = 0.748). These different impacts of MGMT status on OS were similar in newly diagnosed GBM patients, elderly GBM patients and recurrent GBM. Among patients receiving TMZ-free treatment, survival benefit in Asian patients was not observed anymore after Bonferroni correction (Asian OS: HR = 0.78, 95% CI 0.64-0.95,  = 0.02, Bon = 0.24,  = 0%; PFS: HR = 0.69, 95% CI 0.50-0.94,  = 0.02, Bon = 0.24). No benefit was observed in Caucasian receiving TMZ-free therapy regardless of Bonferroni adjustment. The meta-analysis highlights the universal predictive value of methylation in newly diagnosed GBM patients, elderly GBM patients and recurrent GBM patients. For elderly methylated GBM patients, TMZ alone therapy might be a more suitable option than radiotherapy alone therapy. Future clinical trials should be designed in order to optimize therapeutics in different GBM subpopulation.</description><identifier>ISSN: 1664-2295</identifier><identifier>EISSN: 1664-2295</identifier><identifier>DOI: 10.3389/fneur.2018.00127</identifier><identifier>PMID: 29619003</identifier><language>eng</language><publisher>Switzerland</publisher><ispartof>Frontiers in neurology, 2018-03, Vol.9, p.127</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29619003$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Yu-Hang</creatorcontrib><creatorcontrib>Wang, Ze-Fen</creatorcontrib><creatorcontrib>Cao, Chang-Jun</creatorcontrib><creatorcontrib>Weng, Hong</creatorcontrib><creatorcontrib>Xu, Cheng-Shi</creatorcontrib><creatorcontrib>Li, Kai</creatorcontrib><creatorcontrib>Li, Jie-Li</creatorcontrib><creatorcontrib>Lan, Jing</creatorcontrib><creatorcontrib>Zeng, Xian-Tao</creatorcontrib><creatorcontrib>Li, Zhi-Qiang</creatorcontrib><title>The Clinical Significance of O 6 -Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis</title><title>Frontiers in neurology</title><addtitle>Front Neurol</addtitle><description>Promoter status of O -methylguanine-DNA methyltransferase ( ) has been widely established as a clinically relevant factor in glioblastoma (GBM) patients. However, in addition to varied therapy schedule, the prognosis of GBM patients is also affected by variations of age, race, primary or recurrent tumor. This study comprehensively investigated the association between promoter status and prognosis in overall GBM patients and in different GBM subtype including new diagnosed patients, recurrent patients and elderly patients. A comprehensive search was performed using PubMed, EMBASE, Cochrane databases to identify literatures (published from January 1, 2005 to April 1, 2017) that evaluated the associations between promoter methylation and prognosis of GBM patients. Totally, 66 studies including 7,886 patients met the inclusion criteria. Overall GBM patients with a methylated status of receiving temozolomide (TMZ)-containing treatment had better overall survival (OS) and progression-free survival (PFS) [OS: hazard ratio (HR) = 0.46, 95% confidence interval (CI): 0.41-0.52,  &lt; 0.001, Bon = 0.017; PFS: HR = 0.48, 95% CI 0.40-0.57,  &lt; 0.001, Bon = 0.014], but no significant advantage on OS or PFS in GBM patients with TMZ-free treatment was observed (OS: HR = 0.97, 95% CI 0.91-1.03,  = 0.08, Bon = 1; PFS: HR = 0.76, 95% CI 0.57-1.02,  = 0.068, Bon = 0.748). These different impacts of MGMT status on OS were similar in newly diagnosed GBM patients, elderly GBM patients and recurrent GBM. Among patients receiving TMZ-free treatment, survival benefit in Asian patients was not observed anymore after Bonferroni correction (Asian OS: HR = 0.78, 95% CI 0.64-0.95,  = 0.02, Bon = 0.24,  = 0%; PFS: HR = 0.69, 95% CI 0.50-0.94,  = 0.02, Bon = 0.24). No benefit was observed in Caucasian receiving TMZ-free therapy regardless of Bonferroni adjustment. The meta-analysis highlights the universal predictive value of methylation in newly diagnosed GBM patients, elderly GBM patients and recurrent GBM patients. For elderly methylated GBM patients, TMZ alone therapy might be a more suitable option than radiotherapy alone therapy. Future clinical trials should be designed in order to optimize therapeutics in different GBM subpopulation.</description><issn>1664-2295</issn><issn>1664-2295</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpNUMtOwkAUnRiNEGTvyswPFDst83JHUNEEhQQSl-S2cwtjplPSmS74Eb_XRjTxbM4rOYtDyC1LJ3mu9H3lsWsnWcrUJE1ZJi_IkAkxTbJM88t_ekDGIXymPXKtc5Ffk0GmBdO9H5Kv7QHp3FlvS3B0Y_feVr30JdKmoisqaPKG8XBy-w689Zg8vs_oOYkt-FBhCwHpum3qJmL7W0G0jaebCLEL1Ho6M52LdN3H6GOgHzYe6MLZpnAQYlPDA_0ZhQQ8uFOw4YZcVeACjn95RLbPT9v5S7JcLV7ns2VyZKmKSclVKRALxGlWSS6NlLziqIxEDUYAL5VEblihM8XNtERhOJRQcDlFrVg-Infn2WNX1Gh2x9bW0J52f__k36RTbHE</recordid><startdate>20180321</startdate><enddate>20180321</enddate><creator>Zhao, Yu-Hang</creator><creator>Wang, Ze-Fen</creator><creator>Cao, Chang-Jun</creator><creator>Weng, Hong</creator><creator>Xu, Cheng-Shi</creator><creator>Li, Kai</creator><creator>Li, Jie-Li</creator><creator>Lan, Jing</creator><creator>Zeng, Xian-Tao</creator><creator>Li, Zhi-Qiang</creator><scope>NPM</scope></search><sort><creationdate>20180321</creationdate><title>The Clinical Significance of O 6 -Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis</title><author>Zhao, Yu-Hang ; Wang, Ze-Fen ; Cao, Chang-Jun ; Weng, Hong ; Xu, Cheng-Shi ; Li, Kai ; Li, Jie-Li ; Lan, Jing ; Zeng, Xian-Tao ; Li, Zhi-Qiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p108t-c58c6eebee42f757d775f5e8d7e9ad6a5c87e5d1b9285d4ce6d5acab574e9813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Yu-Hang</creatorcontrib><creatorcontrib>Wang, Ze-Fen</creatorcontrib><creatorcontrib>Cao, Chang-Jun</creatorcontrib><creatorcontrib>Weng, Hong</creatorcontrib><creatorcontrib>Xu, Cheng-Shi</creatorcontrib><creatorcontrib>Li, Kai</creatorcontrib><creatorcontrib>Li, Jie-Li</creatorcontrib><creatorcontrib>Lan, Jing</creatorcontrib><creatorcontrib>Zeng, Xian-Tao</creatorcontrib><creatorcontrib>Li, Zhi-Qiang</creatorcontrib><collection>PubMed</collection><jtitle>Frontiers in neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Yu-Hang</au><au>Wang, Ze-Fen</au><au>Cao, Chang-Jun</au><au>Weng, Hong</au><au>Xu, Cheng-Shi</au><au>Li, Kai</au><au>Li, Jie-Li</au><au>Lan, Jing</au><au>Zeng, Xian-Tao</au><au>Li, Zhi-Qiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Clinical Significance of O 6 -Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis</atitle><jtitle>Frontiers in neurology</jtitle><addtitle>Front Neurol</addtitle><date>2018-03-21</date><risdate>2018</risdate><volume>9</volume><spage>127</spage><pages>127-</pages><issn>1664-2295</issn><eissn>1664-2295</eissn><abstract>Promoter status of O -methylguanine-DNA methyltransferase ( ) has been widely established as a clinically relevant factor in glioblastoma (GBM) patients. However, in addition to varied therapy schedule, the prognosis of GBM patients is also affected by variations of age, race, primary or recurrent tumor. This study comprehensively investigated the association between promoter status and prognosis in overall GBM patients and in different GBM subtype including new diagnosed patients, recurrent patients and elderly patients. A comprehensive search was performed using PubMed, EMBASE, Cochrane databases to identify literatures (published from January 1, 2005 to April 1, 2017) that evaluated the associations between promoter methylation and prognosis of GBM patients. Totally, 66 studies including 7,886 patients met the inclusion criteria. Overall GBM patients with a methylated status of receiving temozolomide (TMZ)-containing treatment had better overall survival (OS) and progression-free survival (PFS) [OS: hazard ratio (HR) = 0.46, 95% confidence interval (CI): 0.41-0.52,  &lt; 0.001, Bon = 0.017; PFS: HR = 0.48, 95% CI 0.40-0.57,  &lt; 0.001, Bon = 0.014], but no significant advantage on OS or PFS in GBM patients with TMZ-free treatment was observed (OS: HR = 0.97, 95% CI 0.91-1.03,  = 0.08, Bon = 1; PFS: HR = 0.76, 95% CI 0.57-1.02,  = 0.068, Bon = 0.748). These different impacts of MGMT status on OS were similar in newly diagnosed GBM patients, elderly GBM patients and recurrent GBM. Among patients receiving TMZ-free treatment, survival benefit in Asian patients was not observed anymore after Bonferroni correction (Asian OS: HR = 0.78, 95% CI 0.64-0.95,  = 0.02, Bon = 0.24,  = 0%; PFS: HR = 0.69, 95% CI 0.50-0.94,  = 0.02, Bon = 0.24). No benefit was observed in Caucasian receiving TMZ-free therapy regardless of Bonferroni adjustment. The meta-analysis highlights the universal predictive value of methylation in newly diagnosed GBM patients, elderly GBM patients and recurrent GBM patients. For elderly methylated GBM patients, TMZ alone therapy might be a more suitable option than radiotherapy alone therapy. Future clinical trials should be designed in order to optimize therapeutics in different GBM subpopulation.</abstract><cop>Switzerland</cop><pmid>29619003</pmid><doi>10.3389/fneur.2018.00127</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-2295
ispartof Frontiers in neurology, 2018-03, Vol.9, p.127
issn 1664-2295
1664-2295
language eng
recordid cdi_pubmed_primary_29619003
source PubMed Central
title The Clinical Significance of O 6 -Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A17%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Clinical%20Significance%20of%20O%206%20-Methylguanine-DNA%20Methyltransferase%20Promoter%20Methylation%20Status%20in%20Adult%20Patients%20With%20Glioblastoma:%20A%20Meta-analysis&rft.jtitle=Frontiers%20in%20neurology&rft.au=Zhao,%20Yu-Hang&rft.date=2018-03-21&rft.volume=9&rft.spage=127&rft.pages=127-&rft.issn=1664-2295&rft.eissn=1664-2295&rft_id=info:doi/10.3389/fneur.2018.00127&rft_dat=%3Cpubmed%3E29619003%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p108t-c58c6eebee42f757d775f5e8d7e9ad6a5c87e5d1b9285d4ce6d5acab574e9813%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/29619003&rfr_iscdi=true